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Short Communication
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Departments of Medical Services and Development Therapeutics, The University of Texas M.D. Anderson
Hospital and Tumour Institute at Houston, Houston, TX 77030.
Introduced into clinical trials in 1963, cytosine
arabinoside (1-,B-arabinofuranosyl cytosine, Ara-C)
proved to be most active agent against acute
leukaemia and showed lesser, but definite, activity
in other cancers (Kremer, 1975). Renewed interest
in short intermittent infusion schedules of Ara-C
was stimulated by a better understanding of the
pharmacokinetic properties of the drug and
mechanisms of tumour resistance. Such short
infusion schedules would avoid the dose-limiting
myelosuppressive toxicity caused by prolonged
infusions (Frei et al., 1969), and allow the
administration of higher doses of Ara-C that may
overcome tumour resistance (Frei & Canellos,
1980). The positive results in patients with
refractory leukaemia and lymphoma (Karenes et al.,
1979; Capizzi et al., 1980; Kantarjian et al., 1983)
prompted the investigation of high-dose Ara-C in
patients with colorectal cancer.
Twenty-eight consecutive patients with
histologically-proven measurable metastatic
colorectal adenocarcinoma were treated with high-
dose Ara-C after informed consent was obtained.
All had clear-cut evidence of progressive disease. All
had prior conventional chemotherapy, 27 of them
with 5-fluorouracil-containing regimens. Ninety-
three percent had a performance status <2 (Table
I). Patients were required to have a granulocyte
count > 1500 I-1, a platelet count of
>100,000pl-, and normal renal and liver function
tests. Response definitions were according to the
World Health Organization criteria. At least two
courses of Ara-C were required before the patient
was considered eligible for response. Patients
starting at the dose of 3gm-2 per course were
continued on chemotherapy for at least two courses
with 6 g m2 per course before evaluation of
response. For pretreatment evaluation, complete
blood counts, SMA 100 and carcinoembryonic
antigen (CEA) levels were determined. Chest
roentgenography and other pertinent radiological
studies for measurable known disease or suspected
Table I High-dose Ara-C in metastatic colorectal
adenocarcinoma.
Patients characteristics
Characteristic
No. of patients entered
Median age in years (range)
Male/Female
Median time from diagnosis of
metastasis to therapy in months
(range)
Median number of prior
chemotherapy regimens (range)
No. of patients with (percent):
*Performance score 0-2
3-4
*Prior resection ofprimary
*Prior radiation therapy
*Organ involvement
Lung
Liver
Bone
Others
Elevated carcinoembyrogenic
antigen level
28
59
17/11
(35-77)
4 (0-48)
1 (1-3)
26 (92)
2 (18)
27 (96)
10 (35)
12 (46)
18 (64)
16 (57)
4 (14)
5 (17)
24 (85)
new disease were performed. Readily measurable
disease was evaluated before each course and with
complete reevaluation after every 2 courses.
Complete blood counts were performed weekly.
Chemotherapy courses were repeated every 3 weeks
depending on bone marrow recovery. Cytosine
arabinoside was given as 3 gm-2 over 2h every
12h. Based on our previous experience in patients
with lymphoma and multiple myeloma, the starting
dose was 3 g m 2 per course. An increment of
3 gm-2 per course was given in the subsequent
cycle if the granulocyte count did not drop
<750p.1- and/or the platelet count <100,000M-1,
and if no other serious nonhaematological toxicity
occurred. A total of 64 treatment courses were given
to all patients. All patients received hydrocortisone
eyedrops 3 times daily to decrease the incidence of
Ara-C related conjunctivitis.
Twenty-six patients were evaluable for response
and 27 patients for toxicity. One patient refused
further chemotherapy after one cycle of Ara-C
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Table II Toxicity of high-dose Ara-C in metastatic colorectal adenocarcinoma (27
patients).
A. Nonhaematologic toxicity % ofpatients
Nausea 48
Diarrhoea 15
Drug Fever 15
Drowziness and Ataxia 11
Mucositis 4
Skin Rash 4
Melena and Epistaxis 4
Febrile Episodes 4
Documented Infection (Pneumonia) 4
B. Haematologic toxicity
Dose level/ Median lowest Median lowest
course granulocyte count Percent with platelet count Percent with
(no. courses x 1038- I granulocyte count x 103j1-l platelet count
evaluable) (range) < 10001 l (range) <100 x 103!d-1
3gm-2 (7) 4.3 (1.8-12.4) 0 200 (155-475) 0
6gm-2 (27) 2.3 (0.4-10.3) 19 129 (11-300) 33
9gm-2 (11) 0.45 (0.1- 4.0) 63 60 (44-304) 73
because of severe nausea and vomiting. Another
patient was lost to follow-up after one cycle of
chemotherapy. No objective tumour response was
noted among the 26 evaluable patients. One patient
had a mixed response in his metastatic pulmonary
disease, but progressive disease was noted even after
3 cycles at the highest tolerable doses per course.
Three patients had stable disease for 3, 4 and 6
months. The remaining 22 patients had progressive
disease.
Table II summarizes the treament-related toxicity.
Myelosuppression was the dose-limiting toxicity.
Neurotoxicity was minimal at the dosages used.
Rebound thrombocytosis (median 821 x IO' p -1,
range 625-1170 x I0 uP1-') was noted in 6 patients
(23%) and occurred 3 weeks after initiation of
chemotherapy, it did not result in any clinical
haemostatic complications. Thrombocytopenia was
usually noted 3 to 7 days earlier than
granulocytopenia; patients also recovered earlier
from thrombocytopenia. No delayed bone marrow
recovery beyond 4 weeks was noted.
Treatment of metastatic colorectal carcinoma
remains a frustrating therapeutic challenge. The
response rate using agents such as 5-fluorouracil,
nitrosoureas, mitomycin alone or in combination is
10 to 30%, with little improvement in survival
(DeVita et al., 1982). This indicates the need to
identify new active agents or regimens for
incorporation into front-line protocols. Experience
with conventional Ara-C in colorectal cancer has
resulted in a 10% response rate (Wasserman et al.,
1975). Similar to other antimetabolites, tumour
resistance to Ara-C is relative. The rationale behind
the renewed interest in high-dose Ara-C is based on
the understanding of the pharmacokinetic
properties, as well as the mechanisms of tumour
resistance. Short infusion schedules would decrease
the dose-limiting myelosuppressive toxicity. This
allows the delivery of higher doses which can
overcome relative tumour resistance as shown in
many experimental and human tumours (Frei &
Canellos, 1980). A model using high dose Ara-C
was proposed (Momparler, 1974) and the initial
trials in patients with leukaemia and lymphoma
suggested encouraging activity. Unfortunately,
similar testing of the drug in patients with
colorectal cancer did not cause any significant
tumour regression. One of the reasons for such
disappointing results could be the very slow tumour
growth pattern which requires a prolonged
exposure to effective chemotherapy for
demonstrable antitumour effect.
In summary, high-dose Ara-C, in the doses and
schedule used, lacks significant antitumour activity
and is not a good candidate for further
investigation in combination chemotherapy for
metastatic colorectal cancer.
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